



Poster Session 2
5:30 – 7:00 p.m.
Wednesday, December 11

P2-01-01: Lifestyle Linked Biomarker is Associated with Poor Prognosis in Estrogen Receptor Negative Breast Cancer	Lindsay Peterson
P2-01-02: Patient’s Preference for Shared Decision Making-Based Distant Metastasis Surveillance and Its Effect on the Quality of Life: A Prospective Pragmatic Trial	Ji-Jung Jung
P2-01-03: Is trastuzumab associated with new-onset hypertension in adolescents and young adults with breast cancer?	Candice Sauder
P2-01-04: Impact of Mobile Healthcare Apps on Patient-Reported Quality of Life after Breast Cancer Surgery: A Randomized Controlled Trial	Yung-Huyn Hwang
P2-01-05: Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Treated Patients with HR+/HER2– Metastatic Breast Cancer	Hope S. Rugo
P2-01-06: Supportive care concerns of young women living with metastatic breast cancer from an ongoing prospective virtual intervention	Kate E Dibble
P2-01-07: The Co-Occurrence of Obesity and Cancer-Related Fatigue and Their Combined Impact on Physical Function in a Nationwide RCT of 456 Breast Cancer Survivors (a URCC NCORP Study).	Lindsey Mattick
P2-01-08: Follow-up in Early and Locally Advanced Breast Cancer Patients: An EORTC QLQ-BCG- ROG study.	Vesna Bjelic-Radiscic
P2-01-09: Patient-reported outcomes in premenopausal breast cancer patients with or without ovarian suppression therapy – a subgroup analysis from a Brazilian prospective cohort	Natalia Nunes
P2-01-10: A real-world evidence study of an online Mindfulness-Based Stress Reduction intervention: Effects on the symptomatic burden of patients with breast cancer	Cynthia Villarreal-Garza

P2-01-11: Supportive Care Service Utilization Among Long Term Metastatic Breast Cancer Survivors	Ashley Pariser Davenport
P2-01-12: Association of Employment Characteristics and Food Insecurity Risks among Women with Breast Cancer	Michael Halpern
P2-01-13: Palliative Care Use and End-of-Life Care Quality in HR+/HER2- Metastatic Breast Cancer	Julia Cohn
P2-01-14: Impact of Psychological Support on Quality of Life, Coping Strategies, and Anxiety and Depression in Breast Cancer Patients: A Comparative Randomized Study	Marina Campione
P2-01-15: Survivorship attributes in women with hormone receptor positive breast cancer at long term follow-up in the CLEAR Study of Late Recurrence.	Ana Elisa Lohmann
P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE project	Rodrigo Sánchez-Bayona
P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy & a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial	Maxwell Lloyd
P2-01-19: Measurement of ADC Targets HER2 and TROP2 in Breast Cancer for Accuracy and Selection	NAY CHAN
P2-01-20: Impact of Exercise on Immune Biomarkers in Benign Breast Tissue from Women with High Mammographic Breast Density (MBD)	Jennifer Ligibel
P2-01-21: Baseline circulating tumor cells (CTCs) predict for progression-free survival (PFS) after ablation on NRG-BR002, a randomized phase II/III study of ablation vs. standard systemic therapy care (SOC) for oligometastatic breast cancer (OMBC).	Wendy Woodward
P2-01-22: NSABP B-31 confirms the prognostic value of the NeoALTTO-developed S5 genomic classifier	Katherine Pogue-Geile
P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC	Xixuan Zhu
P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trial	Ulrike Heber

P2-01-25: Circulating tumor DNA clearance by neoadjuvant chemotherapy or breast surgery detected using an ultrasensitive ctDNA MRD assay in early breast cancer	Luc Cabel
P2-01-26: Carboplatin added to neoadjuvant chemotherapy in a randomized phase II study: Complex DNA based biomarkers predict response in hormone receptor positive and triple negative breast cancer.	Olav Engebraaten
P2-01-27: Utility of Plasma Circulating DNA Tumor Fraction in Bone-Only Metastatic Breast Cancer: A Real-world Outcomes Study	Deloris Veney
P2-01-28: Expression of Antibody-Drug Conjugate targets in tumor and normal tissue from patients with metastatic breast cancer	Kristien Borremans
P2-01-29: Prognostic value of circulating tumor DNA in metastatic breast cancer	Luc Cabel
P2-01-30: Gene Expression patterns in early ER+/HER2- breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial	Evangelos Tzoras
P2-02-01: Enhancing chemotherapy sensitivity in triple-negative breast cancer through knockdown of the 'Dark' druggable gene SCYL3	Hannah Engebretson
P2-02-02: CHEMOTHERAPEUTIC TOPOISOMERASE 2 POISONS GENERATE TREX1 RESISTANT DNA FRAGMENTS THAT INDUCE A POTENT cGAS/STING RESPONSE	Kienan Savage
P2-02-03: The RAR gamma nuclear receptor agonist IRX5010 has combination inhibitory effects with an anti-PDL-1 checkpoint inhibitor on the growth of EMT-6 triple negative breast cancer	Martin Sanders
P2-02-04: Investigating Semaphorin7a in Mammary Gland Involution and Postpartum Breast Tumorigenesis	Lauren Cozzens
P2-02-05: Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models	Stefano Rossetti
P2-02-06: Molecular heterogeneity in adjacent normal tissue among Chinese breast cancer patients	Hela Koka
P2-02-07: Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions	Stefano Rossetti
P2-02-08: Chromosome 8q gain-related transcription factor MYBL1 is a critical regulator in triple-negative breast cancer	Akihiro Fujimoto

P2-02-09: Novel Intramolecular BRCT Domain Interaction with ECT2 C-terminal Intramolecular Interaction Domain Regulates GEF Activity and Tumorigenesis	Jinyu Lu
P2-02-10: Inhibition of the Kif11 mitotic protein kills TP53-mutant triple-negative breast cancer cells	Amanda Lanier
P2-02-11: Unveiling the subtype-specific role of PTPRK in triple-negative breast cancer: Implications for targeted therapies	Xiangyi Liu
P2-02-13: Metformin prevents tumor cell growth and invasion of human hormone receptor positive breast cancer (HR+BC) cells via FOXA1 inhibition	SeungBaek Lee
P2-02-14: C1QL1 inhibits breast cancer through HSP90 α /VCP-ERS/UPR axis	Ningning Zhang
P2-02-15: Engineered macrophages secreting TRAIL achieve immunotherapy for triple-negative breast cancer by inhibiting the Wnt/ β -catenin signaling pathway	Chuangui Song
P2-02-16: Therapeutic Decision-Making in Breast Cancer: The Contribution of Artificial Intelligence	Marina Campione
P2-02-17: Race and outcomes in HR+/HER2- breast cancer: how tissue morphology and molecular pathways contribute to worse outcomes in Black women	Daniel Cook
P2-02-18: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project	Brittany McKelvey
P2-02-19: Virtual Multiplex Immunofluorescence Identifies Lymphocyte Subsets Predictive of Response to Neoadjuvant Therapy	Anran Li
P2-02-20: Prediction of Axillary Lymph Node Metastasis in Breast Cancer using Intraoperative Fluorescence Multi-modal Imaging	He Sun
P2-02-21: Predicting HER2-targeting antibody-drug conjugate dosing regimens and quantifying immune system contributions to efficacy using agent-based computational modeling	Melissa Calopiz
P2-02-22: BCM PDX Insights Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management to Facilitate Pre-clinical Studies in Breast Cancer	Michael Lewis
P2-02-23: Open	
P2-02-24: Evaluating ChatGPT as an educational resource for patients with Breast cancer: A preliminary investigation	Zunairah Shah

P2-02-25: Predicting the response of triple negative breast cancer to neoadjuvant systemic therapy via biology-based modeling and habitat analysis	Casey Stowers
P2-02-26: Development of AI diagnosis of immunohistochemistry for ER and HER2 in breast cancer.	Kaori Terata
P2-02-27: Automating Breast Cancer Relapse Identification in Pathology Reports Using Natural Language Processing	Jaimie Lee
P2-02-28: Challenges and Opportunities in Early Diagnosis of Breast Cancer: Utilizing Clinical Decision Support Platforms for Improved Detection	Bea Bakshi
P2-02-29: AI-based Clinical Decision Support System (CDSS) for predicting response to primary systemic therapy in early breast cancer: multimodal modeling and pathology contribution.	Barbara Bussels
P2-03-01: Sexual health in unpartnered women after breast cancer: Report from a joint analysis of two international multi-site prospective cohorts of young breast cancer survivors	Sharon Bober
P2-03-02: Fertility and ovarian function preservation in young women with breast cancer: A comparative analysis of two prospective cohort studies in Mexico and Italy	Cynthia Villarreal-Garza
P2-03-03: Aromatase inhibitor (AI) use in a phase I, single arm, prospective study to evaluate the treatment of genitourinary syndrome of menopause (GSM) with platelet rich plasma (PRP) in women with a history of breast cancer.	Anita Chen
P2-03-04: Assessing and Addressing the Distinct Psychosocial Needs of Young Women with Breast Cancer	Shari Goldfarb
P2-03-05: AI-Powered Breast Cancer Survivorship Support: A Comparative Analysis of ChatGPT and Gemini in Providing Evidence-Based Lifestyle Guidance	Jasmin Hundal
P2-03-06: Factors Associated with Pregnancy and Postpartum Treatment After Endocrine Therapy Interruption in Breast Cancer Patients	Risa Kasahara
P2-03-07: Neoadjuvant (Z)-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor 2 (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE Study	Sarah Premji
P2-03-08: Influence of Work Schedule Flexibility on Nutrition and Physical Activity Among Employed Breast Cancer Survivors	Jasmin Hundal
P2-03-09: Breast Cancer Surgery and Its Quality-of-Life Outcomes: A Study of São Paulo Public Employees	Marcelo Antonini

P2-03-10: Functional Disability and Adverse Mental Health Outcomes among Breast Cancer Survivors: A US National Survey Study	Jincong Freeman
P2-03-11: Health-Related Quality of Life in BREAST trial (Brazilian outcome for Metastatic Breast Cancer): clinical outcomes of HR+, HER2+ breast cancer and its relationship with access to healthcare in Brazil	Luciola Leite de Barros
P2-03-12: Reducing Stress and Improving Quality of Life for Adult Breast Cancer Patients via delivery of monthly non-medical essential services for up to six months during treatment	Danna Remen
P2-03-13: Quality of life in young Hispanic women with breast cancer: Long-term results from a large prospective cohort	Cynthia Villareal-Garzac
P2-03-14: PATIENT REPORTED OUTCOMES AND LYMPHEDEMA IN NODE-POSITIVE BREAST CANCER IN THE EARLY POSTOPERATIVE PERIOD AFTER NEOADJUVANT CHEMOTHERAPY IN THE PROSPECTIVE NEOSENTITURK-trial MF18-03	Neslihan Cabioglu
P2-03-15: Identifying pre-habilitation targets for the mitigation of long-term side effects of chemotherapy in patients with early breast cancer	Lyndsay Cooper
P2-03-16: Prevalence of PIK3CA/AKT1/PTEN and other genomic alterations in primary and recurrent tumor tissue: exploratory analysis from the Phase 3 CAPItello-291 clinical trial	Javier Cortés
P2-03-17: Targeting NR2F2 overcomes multiple forms of endocrine resistance	Yanyan Cai
P2-03-18: Lymph node metastasis of breast cancer: subclonal selection for high lipid metabolism from the primary tumor	Yue Zhou
P2-03-19: Capiasertib-fulvestrant for patients w/ HR-pos/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trial	Komal Jhaveri
P2-03-20: Correlation of cell cycle arrest and intrinsic subtype with pathologic nodal status after neoadjuvant endocrine therapy – results from the Palbociclib and Endocrine therapy for Lobular breast cancer Preoperative Study	Anna Weiss
P2-03-21: Longitudinal Monitoring of ctDNA for Disease Surveillance in Older Women with ER+ Breast Cancer on Primary Endocrine Therapy to Facilitate Surgical De-Escalation: A Prospective, Pragmatic, Hybrid-Decentralized Trial with Correlative Analyses	Neil Carleton

P2-03-22: Shallow whole genome sequencing of cell free DNA to predict response to CDK4/6 inhibitor treatment in ER+/HER2-metastatic breast cancer	Olga Oikonomidou
P2-03-23: Charting the longitudinal mutational landscape of triple negative breast cancer	Olga Oikonomidou
P2-03-24: Cost-Effectiveness of CYP2D6 Genotyping in the Management of Tamoxifen Therapy for Breast Cancer Patients: A Focus on Adverse Events	Isabel Blancas
P2-03-25: Characterization of patritumab deruxtecan activity in breast cancer (BC) patient-derived xenograft (PDX) models	Andreu Òdena
P2-03-26: Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer (eTNBC/mTNBC): primary results and pathology insights from the global retrospective observational VANESSA study	Corrado D'Arrigo
P2-03-27: Prevalence of actionable genomic alterations (GA) and predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitor (ICI) effectiveness in HR(+)HER2(-) metastatic breast cancer (MBC)	Mariya Rozenblit
P2-03-28: Immune-based gene expression signature determines clinical efficacy of CDK4/6i in HR+HER2- breast cancer	Ester Ballana
P2-03-29: Upregulation of senescence signatures and interferon-signalling after short-term pre-operative CDK4/6 inhibitor – gene expression analysis from the POP and ABC-POP trials	Julia Dixon-Douglas
P2-03-30: Association of ctDNA in patients with long-term outcome of breast cancer patients undergoing neoadjuvant treatment in the randomized ABCSG 34 clinical trial	Daniel Egle
P2-04-01: MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells	Nami Yamashita
P2-04-02: TRIB3 regulates lipophagy and drives the metastasis of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway	zirong jiang
P2-04-03: Progesterone Receptor-Stimulated MicroRNAs Regulate Breast Cancer Proliferation	Motoki Takaku
P2-04-04: Integrated stress response-upregulated mitochondrial SLC1A5var enhances glucose dependency of human breast cancer cells	Sheng-Fan Wang
P2-04-05: The dynein regulator LIS1 maintains cell cycle progression and DNA integrity in TNBC, and can be targeted to improve paclitaxel response	Parth Majmudar

P2-04-06: Enhancement of TGF- β Receptor Inhibitor Efficacy through CD44 Suppression in Claudin-low Breast Cancer	Ryoichi Matsunuma
P2-04-07: Dual function of PRAK in TP53-associated breast cancer metastasis	Jingjing Liu
P2-04-08: Functions of KLF5 in the cell cycle and breast cancer cell proliferation	Xiaoyun Mao
P2-04-09: A Novel Role of IP6K2 in Regulating Host Cell Death through p21-mediated cell cycle arrest during HSV-1 oncolytic virus Therapy	Zhijian Huang
P2-04-10: ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ER α Stabilization	Han Li
P2-04-11: Selective Pre-clinical Targeting of CD44+ ADAR1+ Triple Negative Breast Cancer	Wenxue Ma
P2-04-12: JAM A expression and its clinical/prognostic value in breast cancer	Yufei Lou
P2-04-13: DIFFERENTIAL SUSCEPTIBILITY OF MESENCHYMAL-LIKE AND BASAL-LIKE TRIPLE NEGATIVE BREAST CANCER CELLS TO STANDARD OF CARE TREATMENT	Ngoc Bao Vuong
P2-04-14: Activation of Target X by Del-1 regulates the progression of TNBC	byeongju kang
P2-04-15: Diagnostic potential of disseminated and circulating cancer cells: A case study of a 34-years-old patient with rapidly progressing breast cancer.	Jonas Roth
P2-04-16: Artificial intelligence can extract important features for diagnosing axillary lymph node metastasis in early breast cancer using contrast-enhanced ultrasonography	Tomohiro Oshino
P2-04-17: The MIRACCL Portal for Comparing Patient and PDX Response Using Cancer Image Features and Genomics in Co-Clinical Breast Cancer Trials	Michael Lewis
P2-04-18: Unlocking the Complete Blood Count as a Risk Stratification Tool for Breast Cancer Using Machine Learning: A Large Scale Retrospective Study	Pedro Henrique Souza
P2-04-19: Identification and Validation of Novel Necroptosis-Related lncRNAs for Prognostic Prediction in Breast Cancer	Zhijian Huang
P2-04-20: Advances and Detection Methods of Metachronous Bilateral Breast Cancer Detection Using AI-Assisted Mammography for Japanese women	Mio Adachi
P2-04-21: Dynamic reporting of treatment related symptoms via ePROs can reversely identify the type of underlying cancer	Andreas Trojan

P2-04-22: Predictive Modeling of Cancer Treatment-Related Cardiac Events in Breast Cancer Patients: Utilizing Dosiomic and Radiomic Features with Machine Learning	Sefika Dincer
P2-04-23: Analytical validation of a high-definition tumor-informed MRD assay demonstrates robust detection at low tumor fractions common in breast cancer	Ashley Acevedo
P2-04-24: CINDERELLA Clinical Trial (NCT05196269): initial Insights into Patient Engagement with an Artificial Intelligence-Based Healthcare Application for Enhancing Breast Cancer Locoregional Treatment Decisions	André Pfob
P2-04-25: Different Pyroptosis Phenotype within Breast Cancer Possess Distinctive Prognosis and Tumor Immune Microenvironment	Ye Hong
P2-04-26: Predicting the prognosis and immunotherapeutic response of triple-negative breast cancer by constructing a prognostic model based on CD8T cell-related immune genes	Zhijian Huang
P2-04-27: Development & Validation of RSC4All: an Artificial Intelligence-driven Machine Learning Nomogram Enhanced with Synthetic Data to Predict RSClin® Results & Guide Adjuvant Treatment of Node-negative HR-positive/HER2-negative Early Breast Cancer	Flavia Jacobs
P2-04-28: Signal Processing Techniques for Investigating the role of Viral Infections in APOBEC3 Enzymes in Tumor Tissue Biopsies	Mohadeseh Soleimanpour
P2-04-29: Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: A SEER population-based study	ziron g jiang
P2-04-30: Harnessing Technology: A Comparative Study of AI versus Manual Scoring in HER2 Ultra-low Breast Cancer	Jeppe Thagaard
P2-05-01: Telemedicine in physical therapy after axillary surgery for early breast cancer	Hans-Christian Kolberg
P2-05-02: IDENTIFICATION OF MOST COMMON CONCERNS IN BREAST CANCER SURVIVORS FROM 2019-2023 IN THE MRW LIFE SURVIVORSHIP PROGRAM	Poornima Saha
P2-05-03: Work Reintegration After Breast Cancer Surgery in São Paulo Public Employees: a cross-sectional observational study.	Marcelo Antonini
P2-05-04: Associations between Hearing/Vestibular Problems and Levels of Physical Function Impairment among Breast Cancer Survivors in a Multiethnic Study Cohort	Jincong Freeman

P2-05-05: Associations among BMI and patient-reported body image dissatisfaction during immediate autologous breast reconstruction: A prospective longitudinal evaluation	Sara Bouhali
P2-05-06: Contemporary media – highlighting a podcast hosted by a breast cancer survivor – to disseminate breast cancer education in a credible, patient-friendly format.	Molly Lindquist
P2-05-07: Combination treatment to prevent and treat oxidative damage to neuronal cells	Matthew Koury
P2-05-08: QUALITY OF LIFE OF PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY: A LOOK AT SEXUALITY	FABIANA MAKDISSI
P2-05-09: Mindfulness as effective complementary therapy in the management of Breast Cancer (BC)	Maria-Eva Perez-Lopez
P2-05-10: Depression and anxiety in patients with breast cancer receiving radiotherapy: A prospective longitudinal study	Shi-Jia Wang
P2-05-11: A prospective cohort study of real-world patient-reported outcomes in HER2-positive early breast cancer patients receiving (neo) adjuvant anti-HER2 based therapy: the preliminary results at 2-cycle treatment	Ke-Da YU
P2-05-12: Experience and perceptions with a phone-based weight loss intervention among survivors of breast cancer (BC) in France: a qualitative study within a randomized clinical trial (RCT).	Antonio Di Meglio
P2-05-13: QUALITY OF SEXUAL LIFE IN YOUNG WOMEN WITH BREAST CANCER IN THE MEDICAL ONCOLOGY SERVICE AT THE HOSPITAL REGIONAL ISSSTE LEON	CARMEN GUADALUPE BERMUDEZ BARRIENTOS
P2-05-15: Challenges and Communication Gaps in Adjuvant Endocrine Therapy for HR+ Breast Cancer Patients in Russia: Insights from an online Survey	Anastasia Danilova
P2-05-16: Interrogating serum thymidine kinase activity with CDK4/6 inhibitor-based therapies: real-world experience in the metastatic and adjuvant setting	Agnieszka Witkiewicz
P2-05-17: The predictive and prognostic value of 18F-FES PET/CT in patients with advanced breast cancer treated with endocrine therapy with cyclin-dependent kinase 4/6 inhibitor	Hye Hyun Jeong, Jae Ho Jeong
P2-05-18: Molecular effects of short pre-operative endocrine therapy in hormone receptor-positive and HER2-negative early breast cancer	Raquel Gómez-Bravo
P2-05-19: An ICG-labeled Novel Trop2 Targeting Peptide for In Vivo and Ex Vivo NIR-II Fluorescence Imaging-guided Breast Cancer Precise Surgery	Kangliang Lou

P2-05-20: Tissue-free minimal residual disease testing in 2,000 consecutive patients with breast cancer: real-world data and case report	Tanmayi Pai
P2-05-21: BRCA1/2 alterations in circulating tumor DNA: correlation with germline origin and impact on survival in breast cancer.	Letizia Pontolillo
P2-05-22: Plasma proteomic profiling of early recurrence of breast cancer	Anupama Praveen Kumar
P2-05-23: Inhibition of de novo fatty acid synthesis demonstrates broad synergistic effects with anti-cancer therapy, alters cellular lipid composition and induces endoplasmic reticulum stress	Naing Lin Shan
P2-05-24: Impact of the gut microbiome on immune-related adverse events (irAE) in HR+/HER2- locally advanced or metastatic breast cancer (MBC) patients (pts) receiving palbociclib, endocrine therapy, and pembrolizumab	Alexis LeVee
P2-05-25: Comparative Study of Droplet-digital PCR and Ultra-sensitive NGS Assay for ctDNA Profiling in Breast Cancer	Binggang Xiang
P2-05-26: Differential TROP2 expression patterns among inflamed tumor microenvironments in HER2-negative breast cancer	Mai Onishi
P2-05-27: Revealing prognostic subtypes and related model of early-stage TNBC	Peifen FU
P2-05-28: High throughput analysis in HER2 positive locally advanced breast cancer (BC): pathological complete response (pCR) and mutational status.	Ida Paris
P2-05-29: Orally bioavailable cyclin A/B-RxL inhibitors elicit antitumor activity in breast cancer patient-derived xenograft models	Cristina Molina-Gutiérrez
P2-05-30: Ki-67 dynamics during neoadjuvant treatment of breast cancer and their added prognostic value to the Neo-Bioscore model: a population-based cohort study	Maria Angeliki Toli
P2-06-01: CBP/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in TNBC	Xueying Yuan
P2-06-02: Identification of Antigenic Determinants in SV-BR-1 derived Cellular Breast Cancer Vaccines	Miguel Lopez-Lago
P2-06-03: Age Conditions the Tumor Microenvironment of Hormone Receptor Positive Breast Cancer	Mackenzie Hawes
P2-06-04: Potential Impact of the Cancer-Associated Fibroblast Secretome in the Tumor Microenvironment	Anjali Agrawal

P2-06-05: Use of breast adipose-derived stromal cells in a 3D spheroid model to recapitulate the triple-negative breast cancer tumor microenvironment	Nicole Cullen
P2-06-06: The Role of iNOS Inhibition in Enhancing Chemotherapy Efficacy by Modulating the Tumor Microenvironment in Obese TNBC Models	Ivonne Uzair
P2-06-07: Function of NR4A1 in Natural Killer Cells	Kenneth Martinez-Algarin
P2-06-08: A Novel SERM Reinvigorates Natural Killer Cells by Uniquely Downregulating DKK1 in Breast Cancer Cells	Kristen Young
P2-06-09: Impact of lipid composition on triple-negative breast cancer progression and survival.	Khudeja Salim
P2-06-10: The transcription factor HLF (Hepatic Leukemia Factor) : a potential therapeutic target in triple negative breast cancer	Ibrahim BOUAKKA
P2-06-11: TBK1 Promotes Growth of Aggressive Breast Cancer by Modulating the Tumor Microenvironment	Lan Phi
P2-06-12: MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity	Junlong Chi
P2-06-13: HOXB13 Expression Induces an Immunosuppressive Tumor Microenvironment in Breast Cancer	Dennis Sgroi
P2-06-14: Calcium-Sensing Receptor Agonist Enhanced Anti-Tumor Activity of Adoptive NK Cell Therapy in Triple-Negative Breast Cancer	Yu Shi
P2-06-15: DCIS-associated myoepithelial cells drive transcriptional alterations in macrophages through up-regulation of integrin $\alpha\beta6$	Michael Allen
P2-06-16: Addressing Thermal and Battery Efficiency in AI Enhanced Portable Ultrasound Screening Protocols for Breast Cancer	Nusrat Zaman Zemi
P2-06-17: An Integrated Analysis of Metastatic Gene Co-expression in Triple-Negative Breast Cancer via Bulk and Single-Cell Transcriptome Data	Melody Hong
P2-06-18: Deep learning-based tumor microenvironment signature predicts progression-free survival in early-stage hormone receptor positive and HER2 negative breast cancer	Firas Khader
P2-06-19: The clinical relevance of infiltrating hematopoietic stem cells in the breast cancer tumor microenvironment	Masanori Oshi
P2-06-20: Use of an AI Algorithm to Determine the Prevalence of Breast Arterial Calcifications in Women Undergoing Screening Mammograms Based on Race, Age and Cancer Status	Chirag Parghi

P2-06-21: Preliminary validation of a multi-modal AI for stratification of early-stage breast cancer patients utilizing a foundation model for digital pathology	Jan Witowski
P2-06-22: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc.	Reshma L. Mahtani
P2-06-23: Using a Machine Learning Model for Prediction of Palbociclib Response in a Single Institution, Real-World Analysis of Patients with ER+ HER2- Advanced Breast Cancer	Xiaojie Zhang
P2-06-24: Effect of an Image-Derived Short Term Breast Cancer Risk Score in the Analysis of Breast Cancer Prevalence in Screening Population by Race and Breast Density	Chirag Parghi
P2-06-25: Is Mammography Artificial Intelligence consistent across race and density?	Chirag Parghi
P2-06-26: nf-hlamajority: a Nextflow pipeline for consensus MHC class I typing and its application to neoantigen identification in breast cancer stromal cells	Kevin Ryan
P2-06-27: Mapping APOBEC Profiles in Breast Cancer Microenvironments: Bridging Bulk and Single-Cell RNA-seq Data	Jake Lehle
P2-06-28: AI-driven feature discovery enables accurate identification of breast cancer biomarkers and histology	Joseph Cappadona
P2-06-29: Automated Breast Density Assessment on Chest CT with a Deep-Learned 3D Ordinal Regression Model	Artur Wysoczanski
P2-06-30: A Machine Learning Platform for In Silico Design of DNA Targeting Cancer Therapeutics Using SwRI's Rhodium® Docking Software	Tristan Adamson
P2-07-02: Predicting and validating up to 5-year risk of triple-negative breast cancer using mammogram images.	Graham Colditz
P2-07-03: Noninvasive imaging of breast cancer and metastasis using TROP2-targeting radiotracer 68Ga-TTP	Yifei Pei
P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study	Elizabeth McDonald
P2-07-05: Performance of the BCSC and MammoRisk (MR) scores with and without PRS313 to predict invasive breast cancer (IBC) risk in the UK Biobank cohort	Elie Rassy
P2-07-06: ClearCoast® MRI System - Intraoperative Magnetic Resonance Imaging for Margin Assessment of Ductal Carcinoma In Situ (DCIS) and Invasive Breast Cancer in Breast Conserving Surgery. MRO - A Controlled Post-Market Study	Marc Thill

P2-07-07: Multiparametric Whole-Body MRI for Reclassification of Oligometastatic Disease in Metastatic Breast Cancer Patients: A Prospective Study	Michela Palleschi
P2-07-08: MRI screening for brain metastases versus SYMptom-directed brain imaging for Patients with Triple neg or HER2+ Metastatic breast cancer: updated primary outcome analysis and preliminary quality of life data from a randomized phase II pilot study	Katarzyna J. Jerzak
P2-07-09: Breast cancer diagnosis using artificial intelligence algorithms	Yumi Kim
P2-07-10: The role of [18F]16 β -Fluoro-17 β -Fluoroestradiol (FES) Positron Emission Tomography (PET) in Predicting Response to Endocrine Therapy (ET)	Nicholas DiGregorio
P2-07-11: The value of baseline staging tests in early stage breast cancer: A retrospective study from the Antwerp University Hospital	Christophe Van Berckelaer
P2-07-12: Associations between demographic and clinicopathologic characteristics and convolutional neural network-derived breast cancer risk scores among women with hormone receptor-positive breast cancer.	Julia McGuinness
P2-07-13: USE OF INDIGO CARMINE FOR DETECTING SENTINEL LYMPH NODES IN BREAST CANCER: INTERIM RESULTS OF A STUDY ON EFFICACY AND SAFETY	Mikhail Voronov
P2-07-14: Head-to-head comparison of the dual-targeting tracer [68Ga]Ga-RM26-RGD and [18F]FDG for PET imaging of breast cancer	Qingyao Shang
P2-07-15: Metabolic tumor burden measured by [18F]FDG PET/CT and outcomes of patients with HER2-negative mBC treated with sacituzumab govitecan or trastuzumab deruxtecan	Romain-David Seban
P2-07-16: Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2-Metastatic Breast Cancer (MBC)	Janice Lu
P2-07-17: Palbociclib in women aged ≥ 70 years as first-line treatment for endocrine-sensitive Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative locally advanced or metastatic breast cancer: final results of PalomAGE	Elisabeth Carola

P2-07-18: Results from PALVEN: A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL2-Positive Metastatic Breast Cancer	Geoffrey Lindeman
P2-07-19: Health-Related Quality of Life with Sacituzumab Govitecan versus Treatment of Physician's Choice in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Meta-Analysis of TROPiCS-02 and EVER-132-002 Trials	Hope S. Rugo
P2-07-20: Sociodemographic Disparities in First-Line (1L) Treatment Patterns and Outcomes in Women With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Metastatic Breast Cancer (mBC) in the United States (US)	Gregory Vidal
P2-07-21: A phase II study of pembrolizumab plus fulvestrant in ER positive, HER2 negative advanced/metastatic breast cancer patients	Nancy Chan
P2-07-22: Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced HR+ breast cancer after CDK4/6i: dose escalation data from the Phase 1b/2 SUMIT-ELA study	Francois-Clement BIDARD
P2-07-23: Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A phase II randomized trial in PIK3CA-mutant hormone receptor-positive metastatic breast cancer	Sherry Shen
P2-07-24: Results from the Phase II Study of ROS1 Targeting with Crizotinib in Advanced E-cadherin Negative Lobular Breast Cancer (ROLo)	Alicia Okines
P2-07-25: Thymidine kinase activity as a prognostic and predictive biomarker in the Phase II PACE trial of CDK4/6 inhibition beyond progression	Guilherme Nader-Marta
P2-07-26: Onvansertib shows synergistic efficacy in combination with paclitaxel in HR+ breast cancer: Mechanistic insights from preclinical models	Sreeja Sreekumar
P2-07-27: Long-term administration of endocrine therapy on the gut microbiota of breast cancer patients between disease-free and recurrence	Ming-Feng Hou
P2-07-28: Treatment de-escalation by omission of chemotherapy & the effect of adding the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer—second interim efficacy analysis of the randomized DETECT V trial	Wolfgang Janni

P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial	Fernando Moreno
P2-07-30: Exploring Treatment Options Following Progression to CDK4/6 Inhibitor in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis	Mariangela Gaudio
P2-08-01: Engaging breast cancer survivors in the United States in research: clinical characteristics and demographics from Susan G. Komen's ShareForCures® first cohort	Jessica Epps
P2-08-02: Effectiveness of cyclin inhibitors in patients with Hispanic metastatic breast cancer: Real-world evidence from the Instituto Oncológico Nacional in Panama	Omar Castillo-Fernandez
P2-08-03: Real-World Treatment Challenges in HR+/HER2- mBC: Results From the RETRACT Survey of 150 US Oncologists	Hope S. Rugo
P2-08-04: A Cohort Study of the effectiveness and tolerability of Trastuzumab Deruxtecan For The Treatment of Metastatic or Locally Advanced HER2-positive Breast Cancer.	Ameer Basta
P2-08-05: Pembrolizumab (P) added to Neoadjuvant Chemotherapy (NACT) for Triple Negative Breast Cancer (TNBC) in a community practice setting: Real World Evidence (RWE) for the effectiveness of the KN -522 regimen	Ramesh Ramanathan
P2-08-06: Comparative Analysis of Pathological Outcomes and Toxicity in Hispanic vs Non-Hispanic Patients Receiving Keynote 522 Regimen: A Retrospective Single Center Experience	Jay Parekh
P2-08-07: Benefit of neoadjuvant Pertuzumab/Trastuzumab therapy on pCR in Peruvian patients with HER2-Positive Breast Cancer	Iris Otoya, Zaida Morante
P2-08-08: Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer	Azadeh Nasrazadani
P2-08-09: Predictors of inadequate ovarian function suppression (OFS) in premenopausal women with hormone receptor (HR)-positive breast cancer receiving a gonadotropin-releasing hormone (GnRH) agonist in combination with endocrine therapy	Maryann Kwa
P2-08-10: Real World Use of Ovarian Function Suppression in Women Younger Than 35 with Early Stage ER+Her2- Breast Cancer	Poornima Saha

P2-08-11: Real-world safety of sacituzumab govitecan in patients with advanced triple receptor-negative breast cancer in a tertiary centre in the United Kingdom	Emma Crewe
P2-08-12: Prediction of Chemotherapy Benefit by MammaPrint [®] in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data	Adam Brufsky
P2-08-13: Effectiveness of Combined Neoadjuvant Pembrolizumab and Chemotherapy in Early Triple-Negative Breast Cancer: Real-World Evidence from Multiple Centers in Asia	Yu-Ting Lin
P2-08-14: Prognostic Value of Real-World Immunohistochemical Changes in Breast Cancer Following Neoadjuvant Chemotherapy	Marcelo Antonini
P2-08-15: From Clinical Trials to Real-World Practice: Treatment Regimens, Pathological Complete Response Rates, and the Addition of Platinum Salts in Patients with Triple- Negative Breast Cancer	Stephan Seitz
P2-08-16: Comparative effects of Ribociclib, Palbociclib, and Abemaciclib on circulating and tumor infiltrating myeloid cells in metastatic breast cancer patients	Nikhila Kethireddy
P2-08-18: De-Escalating Axillary Surgery in Nigeria: a phase II Single Arm Trial Protocol	Gregory Knapp
P2-08-19: Delineating The Role of Normal Cell Types In Breast Cancer (Breast Cell Atlas)	Nelly Hernandez
P2-08-20: ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study	Virginia Kaklamani
P2-08-21: ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study	Aditya Bardia
P2-08-22: Effectiveness and implementation of a decision support tool to improve surgical decision-making in young women with breast cancer: The CONSYDER Study	Shoshana Rosenberg
P2-08-23: Evaluation of Pathological Complete Response & Immunomodulatory Effects Following Intratumoral Injection of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: A Phase II Study INVINCIBLE-4-SAKK 66/22	Ursina Zürrer-Härdis

P2-08-24: Exploring the correlation between Superparamagnetic Iron Oxide counts at the axilla and Ductal Carcinoma In Situ size after Primary Breast Surgery: Preliminary Study Results	Bernardo Martinez-Leal
P2-08-25: FITWISE: Feasibility study of tirzepatide for weight loss intervention in early stage hormone receptor positive/HER2 negative breast cancer	Coral Omene
P2-08-26: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer	Robert Maganini
P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd)	BARBARA PISTILLI
P2-08-28: Implementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older Breast Cancer patients (IMPORTANT trial) – a pragmatic randomized-controlled trial	Emanuela Risi
P2-08-29: Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study (LaPemERLA)	Yoon-Sim Yap
P2-08-30: Longitudinal measurement of serum Progranulin (PGRN/GP88) in metastatic breast cancer patients enrolled in a prospective study.	Ginette Serrero
P2-09-01: Preliminary Findings from the Breast Cancer Combined Visualization And Characterization Tools (bCOMBAT): Low-Dose PEM and Liquid Biopsy Study	Vivianne Freitas
P2-09-02: Two Years Post-COVID-19: Evaluating the Impact on Brazil's Mammographic Screening Program	André Mattar
P2-09-03: USING OF SULPHUR HEXAFLUORIDE (SF6) FOR DETECTION OF SENTINEL LYMPH NODE IN OUTPATIENT PRACTICE: PRELIMINARY RESULTS FROM AN EFFICACY AND SAFETY STUDY	MARIIA SHARAVINA
P2-09-04: A Randomized Study Assessing Interventions to Improve Comfort During Screening Mammography	Nikki Verma
P2-09-05: Evaluating the Impact of Mammographic Screening on 5-Year Breast Cancer Survival: A Propensity Score-Adjusted Retrospective Cohort Study in a Tertiary Hospital in São Paulo, Brazil	Rodrigo Goncalves

P2-09-06: Bi-annual mammography does not detect more local recurrences than annual mammography in Asian female patients with breast cancer	Byeongju Kang
P2-09-07: Diagnostic performance of TILs-US Score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer	Hideo Shigematsu
P2-09-08: Correlating Breast Density with FDG-avidity on PET Imaging	YiLi Zhao
P2-09-09: Image-based breast cancer risk assessment based on dense mammographic tissue subtypes	Andre Khalil
P2-09-10: Accuracy of stereotactic vacuum-assisted breast biopsy for investigating suspicious calcifications in 2,274 patients a Public Hospital in Brazil	André Mattar
P2-09-11: Improved Prediction of Axillary Lymph Node Metastasis in Early-Stage Breast Cancer Using Deep Learning on Routine Mammography	Daqu Zhang
P2-09-12: A Public Health Initiative To Enhance Screening Mammography (MMG) In Northeast Argentina Utilizing A Novel Thermal Screening Device & Breast Cancer Risk Assessment	Karina Maidana
P2-09-14: Diagnostic Accuracy assessing residual disease in breast cancer patients receiving neoadjuvant systemic therapies (NST) is comparable between contrast enhanced mammography (CEM) & breast magnetic resonance imaging (MRI) across various cancer subtypes	Whitney Harris
P2-09-16: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancer	Virginia Borges
P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/HER2- advanced breast cancer: the Linux trial	Lei Fan
P2-09-18: Comparison of Suboptimal vs. Adequate Ovarian Suppression during Adjuvant Endocrine Therapy for Premenopausal Women with Breast Cancer: An Exploratory Analysis of the PREFER and GIM 23 Studies	Simone Nardin
P2-09-19: Efficacy of cyclin-dependent kinase 4/6 inhibitor + endocrine therapy in patients w/ hormone receptor-positive, HER2-negative advanced or metastatic breast cancer w/ liver or lung only metastases: a US Food & Drug Administration pooled analysis	Raissa Kentsa

P2-09-20: Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2-advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials	Yoon-Sim Yap
P2-09-21: Low-level Aurora kinase A (AURKA) amplification as a novel personalized biomarker of CDK4/6 inhibitor (CDK4/6i) resistance in patients with hormone-receptor positive (HR+) metastatic breast cancer	Seth Wander
P2-09-22: First-line inavolisib/placebo + palbociclib + fulvestrant in PIK3CA-mutated, hormone receptor+, HER2- locally advanced/metastatic breast cancer w/ relapse during/within 12 months of adjuvant endocrine therapy completion: INAVO120 long-term safety	Cristina Saura
P2-09-23: Differential outcomes of patients with HR-positive/HER2-negative metastatic breast cancer and a pathogenic BRCA1/2 or PALB2 variant under first line CDK4/6 inhibition	Timothé Guinel
P2-09-24: Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial	Ana Garrido-Castro
P2-09-25: Subgroup Analyses From the Phase 3 EVER-132-002 Study of Asian Patients With HR+/HER2- Metastatic Breast Cancer	Joohyuk Sohn
P2-09-26: Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 study	Claudio Vernieri
P2-09-27: Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor-positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)	Darian Louthan
P2-09-28: Dalpiciclib plus endocrine therapy for visceral crisis in advanced breast cancer: a multicenter, prospective, external controlled phase 2 study	Hongnan Mo
P2-09-29: Landscape analysis of breast cancer ovarian metastases reveals biology and potential therapeutic targets	Steffi Oesterreich

P2-09-30: Real-world comparative efficacy of CDK4/6 inhibitors in first-line treatment of HR+/HER2- metastatic breast cancer	Adam Brufsky
P2-10-01: Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population	Bo-Fang Chen
P2-10-02: SACISUR, results of a real-world evidence observational study of the use of Sacituzumab-Govitecan (SG) in triple negative metastatic breast cancer (mTNBC) clinical practice in the south of Spain.	Alejandro Falcón-González
P2-10-03: Real world outcomes of adjuvant chemotherapy in invasive lobular carcinoma of the breast: a retrospective cohort from a reference center in Brazil	Raelson Miranda
P2-10-04: Effectiveness and toxicity profile of pertuzumab in combination with trastuzumab and taxane in patients with HER2 positive metastatic breast cancer treated in the Costa Rican Health Care System	Priyanka Khanna
P2-10-05: Survival in Older Women Receiving Adjuvant Radiation Monotherapy vs. Endocrine Monotherapy Following Lumpectomy	Jennifer Plichta
P2-10-06: Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: a multicentre international retrospective cohort study	Luca Visani
P2-10-07: Practice patterns and survival analysis of early-stage HER-negative breast cancers with low and intermediate levels of hormone receptor expression: a 2018-2020 US National Cancer Database analysis	Dionisia Quiroga
P2-10-08: The Impact of Time-to-Surgery (TTS) for Breast Cancer Prognosis After Neoadjuvant Chemotherapy	Xin Wang
P2-10-09: Can an AI-based Clinical Decision Support System (CDSS) in the treatment decision-making process for breast cancer contribute to healthcare cost reduction ?	Barbara Bussels
P2-10-10: Integration of Novel Antibody–Drug Conjugates in Advanced HER2-low, Hormone Receptor-positive and Triple-negative Breast Cancer	Kemi Obajimi
P2-10-11: Utilization and impact of endocrine therapy in male patients with early breast cancer – results from a large German real-world claims data analysis	Dominik Dannehl
P2-10-12: Pembrolizumab in Early Triple-negative breast cancer: Real world data in Hispano-American women (PETRHA) - Initial results	Daniela Vazquez-Juarez

P2-10-13: The Real World Practice of Prospectively Breast Cancer Screening Program for High Polygenic Risk Score Population in Taiwan	Yu-Wen Weng
P2-10-14: HER2 evolution in breast cancer: Evidence from an AI-assisted real-world data analysis of 3 million women in a diverse urban population	Francisco Esteva
P2-10-15: Reproducibility of the interactions of race on outcomes and toxicities associated with treatment of HER2+ Breast Cancer across databases	Britney Fitzgerald
P2-10-16: A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT)	Ting Bao
P2-10-17: A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician's choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01)	Pedram Razavi
P2-10-18: A study to evaluate the safety and efficacy of vosilasarm (EP0062), an oral SARM, as monotherapy and in combination with standard of care regimens in patients with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer	Joyce O'Shaughnessy
P2-10-19: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer	Ciara O'Sullivan
P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)	Joyce O'Shaughnessy
P2-10-21: ADELA: A randomized, phase 3, double-blind, placebo-controlled trial of elacestrant plus everolimus versus elacestrant in ER+/HER2-advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) plus CDK4/6i	Antonio Llombart-Cussac
P2-10-22: APOBEC3 as a Biomarker of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Pilot Study	Iman Doostan
P2-10-23: ASSESSING CLINICAL FEATURES AND OUTCOME OF BREAST CANCER IN PALB2 MUTATION CARRIERS: AN EUROPEAN MULTICENTRIC RETROSPECTIVE HOSPITAL-BASED COHORT CONTROL STUDY (PALBREAST)	Laura Cortesi

P2-10-24: ASTRO-VAC CNS : Bria-IMT in the Management of Tumor Agnostic Metastatic CNS Lesions	Sailaja Kamaraju
P2-10-25: AXSANA: Status of the international prospective multicenter cohort study evaluating different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)	Steffi Hartmann
P2-10-26: Adjuvant pembrolizumab and chemotherapy or surveillance in Early Triple Negative breast cancer with high stromal tumor-infiltrating lymphocytes (sTILs) score (ETNA)	Elie Rassy
P2-10-27: An Open Label Study of BTX-A51 in Patients with ER+/HER2- GATA3 Mutant and Wild Type Metastatic Breast Cancer	Zung Thai
P2-10-28: COMPASS-TNBC - A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety and anti-tumor activity of novel therapeutics in patients with early relapsed mTNBC. Module 1: Dato-DXd & Module 2: Dato-DXd + durvalumab.	Thomas Grinda
P2-10-29: Cascade Testing in Racially/Ethnically Diverse Relatives of Patients with Breast or Ovarian Cancer (CASSIE)	Alissa Michel
P2-10-30: Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients with HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade - CHERRY-PICK Trial (LACOG 0721)	Sérgio Daniel Simon
P2-11-01: Comprehensive spatially resolved single-cell analysis of immunotypes in triple-negative breast cancer revealed the central role of intratumoral MHC class II expressions	Yi Liu
P2-11-02: Is Adjuvant Chemotherapy Needed in Small Node-Negative Triple Negative Breast Cancer?	Joon Suk Moon
P2-11-03: Quantification of Breast Cancer 1 gene (BRCA1) promoter methylation in individuals with and without cancer using cell-free DNA	Francesca Menghi
P2-11-04: Incidence and pattern of central nervous system recurrence in TNBC according to response after neoadjuvant treatments	Thomas Grinda
P2-11-05: Accurate and cost-effective reconstruction of TNBC heterogeneity through 3D digitization of core needle biopsies	Jeffrey Sheridan
P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial	Li Chen

P2-11-07: Open	
P2-11-08: Spatial transcriptomic analysis for tumor infiltrating immune microenvironment modulation by neoadjuvant pembrolizumab with chemotherapy for patients with triple negative breast cancer	Ji-Yeon Kim
P2-11-09: Adding Carboplatin to neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC): a systematic review and meta-analysis	Beatrice Ruffilli
P2-11-10: Assessing the Differential Response to Immunotherapy in BRCA1/2 Mutation Carriers with Triple-Negative Breast Cancer	Minna Lee
P2-11-11: Clinicopathological features predictive of neoadjuvant immune checkpoint inhibitor benefit in triple-negative breast cancer	Shipra Gandhi
P2-11-12: Use of the prognostic H&E stromal tumor-infiltrating lymphocytes score and the predictive 27-gene IO score to identify patients with stage I TNBC who may benefit from immune checkpoint inhibitor-based, chemo de-escalated curative-intent therapy.	Erin Hong
P2-11-13: Retrospective validation of digital twin-based prediction of personalized triple negative breast cancer response to neoadjuvant therapy regimens	Chengyue Wu
P2-11-14: Treatment Patterns and Safety of Adjuvant Therapy After Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer in a Real-World Scenario: The Neo-Real Study	Renata Bonadio
P2-11-15: Axillary Pathologic Complete Response in Triple-Negative Breast Cancer Patients with Mammary Pathologic Complete Response: A Systematic Review	Yedda Reis
P2-11-16 Characterization of disseminated tumor cells (DTCs) in patients with triple-negative breast cancer (TNBC)	Anne Eckardt
P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial	Hans-Christian Kolberg
P2-11-18: Patterns of Treatment in Older Patients with Early-Stage Triple Negative Breast Cancer	Mohammad Abbas

P2-11-19: Unique kinetics of myeloid derived suppressor cell (MDSC) accumulation associated with immune related adverse events (irAEs) in patients with early stage triple negative breast cancer (eTNBC) receiving neoadjuvant chemo-immunotherapy	Alberto Montero
P2-11-20: Discovering Co-driver Genes and Pathways of Mutant TP53 in Breast Cancer by CRISPR Screening and Multi-omics Approaches	Lilian Nwachukwu
P2-11-21: Characterisation of treatment and outcomes for adenoid cystic carcinoma as a distinct clinical sub-type of triple negative breast cancer	Fiona Britton
P2-11-22: Tolerance of Neoadjuvant Chemotherapy in Combination with Immunotherapy in Older Patients with Triple Negative Breast Carcinoma: The MSKCC Experience	Abha Kulkarni
P2-11-23: Impact of age on neoadjuvant chemo-immunotherapy (IO) administration and outcomes in patients with early-stage triple-negative breast cancer (TNBC)	Alexis LeVee
P2-11-24: Racial and ethnic disparities in treatment outcomes of patients with early-stage triple-negative breast cancer following neoadjuvant chemoimmunotherapy	Megan Wong
P2-11-25: Comparison of Outcomes Among Women with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy According to Age	Regina Matar-Ujvary
P2-11-26: Adjuvant chemotherapy in lymph node-negative, T1 triple-negative breast cancer	Jesus anampa
P2-11-27: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab vs. Treatment of Physician's Choice in Patients With TNBC Who Received Neoadjuvant Therapy & Did Not Achieve a Pathological Complete Response at Surgery	Heather McArthur
P2-11-28: Intra-arterial chemotherapy for triple-negative breast cancer: a systematic review	Mariano Belfort Santos
P2-11-29: IMPACT OF GERMLINE MUTATIONS ON pCR IN TRIPLE NEGATIVE BREAST CANCER PATIENTS TREATED WITH PEMBROLIZUMAB PLUS CHEMOTHERAPY: THE TIGER STUDY	Andrea Botticelli
P2-11-30: RAD51AP1 Inactivation Induces Synthetic Lethality of PARP Inhibitors in Breast Cancer Patients Irrespective of BRCA1/2 mutation	Jabunnesa Khanom
P2-12-01: Survival Outcomes after Pathologic Complete Response with Neoadjuvant Endocrine Therapy vs. Neoadjuvant Chemotherapy	Jennifer Plichta

P2-12-02: Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database	Paolo Tarantino
P2-12-03: The effect of Abemaciclib plus fulvestrant on overall survival in hormone-receptor positive, HER2-negative breast cancer that progressed on endocrine therapy – Comparing Real-World outcomes in England to MONARCH 2	Emma Kipps
P2-12-04: Impact of Weight and Weight Variation in Adolescent and Young Adult (AYA) Women with Invasive Breast Cancer	Nerea Lopetegui-Lia
P2-12-05: Retrospective Study of Drug-Induced Interstitial Lung Disease in Breast Cancer Patients Treated at Mayo Clinic between the Years of 2018-2023 (Real World Experience)	John Fanous
P2-12-06: Key factors influencing patient preferences for BRCA testing and adjuvant therapy in HER2-negative early breast cancer	Kathryn Mishkin
P2-12-07: Effectiveness of Predictive Calculators for Breast Cancer Recurrence: A Comparative Study with the 21-Gene Score	Iris Otoyá
P2-12-08: Real world progression-free survival after CDK4/6 inhibitors plus endocrine therapy: results from the multicenter SISTER study	Pier Paolo Maria Berton Giachetti
P2-12-09: Clinical, genetic and immunological features, HER2-low expression and treatment patterns in a large population of male breast cancer patient with long-term follow up	Fabio Giardi
P2-12-10: Dynamic Changes in Breast Cancer Immunochemistry Biomarkers at Recurrence and Their Impact on Survival	Katia Roque
P2-12-11: Lobular breast cancer: diagnostic complexity and delays to surgery.	Hannah Lennon
P2-12-12: Impact of the addition of pembrolizumab to neoadjuvant chemotherapy in triple negative breast cancer in Ireland: a retrospective, multi-centre, real-world study	Karine Ronan
P2-12-13: Clinico-Pathological Characteristics and Incidence Trends of Breast Cancer in Young Women: A 10-Year Single Institution Retrospective Study	Francisco Javier Muñoz i Carrillo
P2-12-14: Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer	Jessica Sharpe
P2-12-15: Trends in Antiemetic Use in Patients Receiving Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer: A Retrospective Analysis of Data from the IntegraConnect PrecisionQ De-Identified Database	Stephan Rosenfeld

P2-12-16: A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED TRIAL EVALUATING EFFECT OF A WIDE SPECTRUM MICRONUTRIENTS SUPPLEMENT ON CANCER RELATED FATIGUE IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT/NEO-ADJUVANT THERAPY	Germano Tarantino
P2-12-17: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors	Yara Abdou
P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE)	Matthew Goetz
P2-12-19: A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions	Julie Nangia
P2-12-20: A Real-World Study of the Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in HER2-low Metastatic Breast Cancer (mBC) among Racial and Ethnic Minorities and Older Populations in the United States	Mackenzie Henderson
P2-12-21: A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Metastatic Breast Cancer: Primary Results of a Prospective Intervention Trial	Deloris Veney
P2-12-22: A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer.	Jie Ouyang
P2-12-23: A phase 2 trial combining tiragolumab and atezolizumab with neoadjuvant or first line chemotherapy for triple negative breast cancer (SKYLINE)	Francois-Clement BIDARD
P2-12-24: A phase I/Ib trial of the CDK4/6 antagonist ribociclib and the HDAC inhibitor belinostat in patients with metastatic triple negative breast cancer and recurrent ovarian cancer with response prediction by genomics (CHARGE).	Talicia Savage
P2-12-25: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007	Julia White

P2-12-26: A phase Ib study of novel combination (New) of low dose oral cyclophosphamide (S) To potentiate axatilimab (A) + retifanlimab (R) in treating metastatic Triple negative breast cancer (NEW START)	Joshua Haney
P2-12-27: A phase Ib study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in patients with refractory HER2-positive metastatic breast cancer.	Santiago Escrivá-de-Romaní
P2-12-28: A prospective randomized, controlled study to evaluate device efficacy for cutting and/or coagulation of tissue during mastectomy procedures.	Jessica Montalvan
P2-12-29: A randomized clinical trial comparing ctDNA-directed therapy change with standard of care in patients with metastatic triple negative breast cancer (mTNBC)	Jessica Sharpe
P2-12-30: A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment (ACT)	Ting Bao